[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367342-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367342-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","proteasome-inhibitor-mg-132-and-pkc-specific-inhibitor-ica-1s-degrade-mutant-p53-and-induce-apoptosis-in-ovarian-cancer-cell-lines","Proteasome Inhibitor MG-132 and PKC-ι-Specific Inhibitor ICA-1S Degrade Mutant p53 and Induce Apoptosis in Ovarian Cancer Cell Lines","","Ovarian cancer remains highly lethal, with p53 mutations and overexpression of atypical protein kinase C iota (PKC-ι) strongly associated with disease progression. This study evaluated how the PKC-ι-specific inhibitor ICA-1S and the proteasome inhibitor MG-132 affect ovarian cancer cell lines. Cell proliferation, cytotoxicity, Western blotting, immunofluorescence, flow cytometry, siRNA, and co-immunoprecipitation were used to map separate pathways. ICA-1S and MG-132 inhibited proliferation; both reduced mutant p53 in ES-2 cells, while MG-132 increased wild-type p53 in HEY-T30 cells. MG-132 additionally triggered apoptosis and autophagy, supporting ICA-1S alone or with MG-132 as a candidate therapy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/proteasome-inhibitor-mg-132-and-pkc-specific-inhibitor-ica-1s-degrade-mutant-p53-and-induce-apoptosis-in-ovarian-cancer-cell-lines/367342/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/proteasome-inhibitor-mg-132-and-pkc-specific-inhibitor-ica-1s-degrade-mutant-p53-and-induce-apoptosis-in-ovarian-cancer-cell-lines/367342.png","ImageObject",300,407,{"name":42,"@type":43},"Rhys","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main research question about ovarian cancer cell lines in this study?","Question",{"text":63,"@type":64},"The study investigates how ICA-1S (a PKC-ι-specific inhibitor) and MG-132 (a proteasome inhibitor) influence proliferation, mutant or wild-type p53 levels, and cell death pathways in ovarian cancer cell lines.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do ICA-1S and MG-132 affect p53 in ES-2 and HEY-T30 cells?",{"text":68,"@type":64},"ICA-1S and MG-132 both decrease mutated p53 in the ES-2 cell line via separate pathways. In contrast, MG-132 increases wild-type p53 in HEY-T30 by inhibiting proteasomal degradation.",{"name":70,"@type":61,"acceptedAnswer":71},"Which cellular effects are reported after MG-132 treatment?",{"text":72,"@type":64},"MG-132 induces apoptosis and autophagy in the ovarian cancer cell lines and suppresses cell proliferation, supporting its potential for treatment strategies targeting mutated p53 and PKC-ι overexpression.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367342,1790248005,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":108,"preview_page_count":33,"preview_urls":145},687207024643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Article  \nProteasome Inhibitor MG-132 and PKC-ι-Specific Inhibitor ICA-1S Degrade Mutant p53 and Induce Apoptosis in Ovarian Cancer Cell Lines  \nMahfuza Marzan, Nuzhat Nowshin Oishee†, Abigail Oluwafisayo Olatunji †, Abiral Hasib Shourav , Radwan Ebna Noor, Aaron Joshua Astalos , James W. Leahy  and Mildred Acevedo-Duncan *  \nAcademic Editor: Vladimir Isachenko  \nReceived: 1 March 2025  \nRevised: 19 March 2025  \nAccepted: 24 March 2025  \nPublished: 26 March 2025  \nCitation: Marzan, M.; Nowshin Oishee, N.; Olatunji, A.O.; Hasib Shourav, A.; Noor, R.E.; Astalos, A.J.; Leahy, J.W.; Acevedo-Duncan, M. Proteasome Inhibitor MG-132 and PKC-ι-Specific Inhibitor ICA-1S Degrade Mutant p53 and Induce Apoptosis in Ovarian Cancer Cell Lines. Int. J. Mol. Sci. 2025, 26, 3035 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms26073035  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \nDepartment of Chemistry, University of South Florida, 4202 E Fowler Ave, CHE 205, Tampa, FL 33620, USA;  \n[mmarzan@usf.edu](mmarzan@usf.edu) (M.M.); [nuzhatn@usf.edu](nuzhatn@usf.edu) (N.N.O.); [abigailolatunji@usf.edu](abigailolatunji@usf.edu) (A.O.O.);  \n[hasibshourav@usf.edu](hasibshourav@usf.edu) (A.H.S.); [noor2@usf.edu](noor2@usf.edu) (R.E.N.); [aaronastalos@usf.edu](aaronastalos@usf.edu) (A.J.A.); [jwleahy@usf.edu](jwleahy@usf.edu) (J.W.L.)  \n* [Correspondence: macevedo@usf.edu](Correspondence: macevedo@usf.edu); Tel.: +1-813-748-4715 † These authors contributed equally to this work.  \nAbstract: Ovarian cancer is the most lethal gynecological cancer, with a 5-year survival rate of approximately 50% . Mutation in the p53 gene and overexpression of the atypical protein kinase C iota (PKC-ι) are two phenomena widely manifested in ovarian cancer. This study investigated the role of PKC-ι-specific inhibitor ICA-1S and proteasome inhibitor MG-132 in ovarian cancer cell lines. To discern the result, cell proliferation assays, cytotoxicity assays, Western blotting, immunofluorescence, flow cytometry, small interfering RNA, and co-immunoprecipitation techniques were applied. ICA-1S and MG-132 were found to inhibit the proliferation of ovarian cancer cell lines significantly. ICA-1S reduced the level of oncogenic PKC-ι as expected. In addition, ICA-1S and MG-132 both were able to decrease the level of mutated p53 in the ES-2 cell line through separate pathways. On the contrary, MG-132 increased the level of wild-type p53 in the HEY-T30 cell line by inhibiting proteasomal degradation. MG-132 also induced apoptosis and autophagy in the ovarian cancer cell lines. We concluded that ICA-1S alone or in combination with MG-132 could be a potential treatment for mutated p53-containing and PKC-ι-overexpressing ovarian cancers.  \nKeywords: ovarian cancer; p53; PKC-ι; proteasome inhibitor MG-132  \n1. Introduction  \nOvarian cancer is the most lethal gynecological cancer in today’s world, and its lethality is mostly attributed to the late stage of diagnosis, resistance against chemotherapeutics such as platinum drugs or taxanes, genetic mutations in tumor suppressors, and hormonal and environmental factors [1–4] . In the year 2020, there were 313,959 new cases of ovarian cancer, and 207,252 women died of this disease worldwide [5] . Of all types, epithelial ovarian cancer is the most common type of ovarian cancer, of which high-grade serous ovarian cancer (HGSOC) is the most aggressive and presents a poor prognosis with a 5-year survival rate of around 25% . Approximately 94–96% of HGSOC cases are characterized by the presence of a mutation in the p53 protein (Mutp53) with loss of function of wild-type p53 (WTp53) or gain of functions of Mutp53 leading to t","cbCaimm2rWW4oGex","https://ap.wps.com/l/cbCaimm2rWW4oGex","pdf",5163664,16,"English","# Introduction\n## Ovarian cancer background and clinical burden\n## p53 mutation and ubiquitin–proteasome regulation\n## Proteasome inhibitors and cellular outcomes\n## PKC-ι role in ovarian cancer pathogenesis","[{\"question\":\"What is the main research question about ovarian cancer cell lines in this study?\",\"answer\":\"The study investigates how ICA-1S (a PKC-ι-specific inhibitor) and MG-132 (a proteasome inhibitor) influence proliferation, mutant or wild-type p53 levels, and cell death pathways in ovarian cancer cell lines.\"},{\"question\":\"How do ICA-1S and MG-132 affect p53 in ES-2 and HEY-T30 cells?\",\"answer\":\"ICA-1S and MG-132 both decrease mutated p53 in the ES-2 cell line via separate pathways. In contrast, MG-132 increases wild-type p53 in HEY-T30 by inhibiting proteasomal degradation.\"},{\"question\":\"Which cellular effects are reported after MG-132 treatment?\",\"answer\":\"MG-132 induces apoptosis and autophagy in the ovarian cancer cell lines and suppresses cell proliferation, supporting its potential for treatment strategies targeting mutated p53 and PKC-ι overexpression.\"}]","Proteasome Inhibitor MG-132 and PKC-ι-Specific Inhibitor ICA-1S Degrade Mutant p53 and Induce Apoptosis in Ovarian Cancer Cell Lines | PDF",1790170375,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/24a3c0012af149880ceaeff2fb65486f.webp",983,1390,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ed8962988b67ecf0b88fd1c1cb818c29.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d45307d8cbf6d3f3c545dd9a48356d68.webp",981,1387,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9c39373533a445f38da8e9cc02eb7b0e.webp",980,1385]